State Street My2027 Corporate Bond ETF (MYCG)
Live price chart, market sentiment, and community perspectives for State Street My2027 Corporate Bond ETF (NASDAQ: MYCG).
Live price chart, market sentiment, and community perspectives for State Street My2027 Corporate Bond ETF (NASDAQ: MYCG).
On our desk, we are monitoring the light liquidity profiles in MYCG closely. With average trading volumes hovering around 2,900 to 4,600 shares and a market cap of roughly $37.5M, execution requires patience. That said, the active target maturity strategy designed to distribute remaining principal and liquidate around December 15, 2027, appeals to clients looking for defined-horizon corporate bond exposure without index replication constraints.
Watching the technical indicators, MYCG has remained exceptionally range-bound near its 50-day moving average of $24.96 and 200-day moving average of $25.01. The tight pricing between $24.90 and $25.14 reflects stable short-term bond market conditions, though investors need to be mindful of active management tracking risks and the fact that the ETF is not guaranteed to replicate any specific index.
From an institutional capital flow perspective, regulatory filings show a healthy mix of interest with 17 hedge funds and large institutions holding $26.7M in Q2 2026. We saw new positions opened by firms like Lido Advisors and JPMorgan Chase, and overall, there were more repeat investments and increased positions than reductions or exits, signaling steady institutional confidence in State Street's target maturity vehicle.
Reviewing the short interest data for MYCG across recent months reveals notable swings. We tracked a sharp 118.8% spike in short interest up to late May, followed by a subsequent 75.4% decline by mid-July. With short-interest ratios staying relatively low between 1.3 and 1.7 days given the average daily volume, these fluctuations indicate tactical positioning rather than a structural short thesis against the fund.
As a risk manager assessing portfolio composition, the 0.15% expense ratio on MYCG makes it a cost-efficient vehicle for short-term corporate debt allocation leading up to its targeted 2027 termination. However, one must account for the lack of individual share redemptions outside of Creation Unit Aggregations and the inherent risk of losing part or all of the investment if market conditions deteriorate.
Explore plasma cleansing, somatic organ swaps, and BCI.